Lexington BioSciences has developed HeartSentry as a first-in-class device for the personalized measurement and monitoring of vascular health to identify cardiovascular disease at its earliest stages.
HeartSentry has been extensively tested to measure the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke, the two leading causes of death worldwide with over 17.5 million deaths each year. *
The significant value of measuring endothelial function is supported by thousands of peer-reviewed studies. For ease of use and familiarity, this life saving technology has been combined into traditional blood pressure cuff equipment.
The unit is designed to communicate via Bluetooth technology to provide up-to-date and accurate readings of an individual’s complete cardiovascular health through electronic monitoring for cardiovascular risk-assessment and to aid treatment effectiveness for the prevention of heart attack and stroke.
HeartSentry targets the rapidly growing self-measurement medical device sector and is deigned for both personal and clinical use. Simplicity and functionality are key elements of the design.
Lexington BioSciences are developers of clinical grade cardiovascular self measurement solutions and HeartSentry is it’s flagship, and first device currently advancing to commercial deployment.